Interview with Ian McCall

What are the benefits of Microdosing psilocybin? | Interview with a Microdosing Expert

In today’s episode, we sit down with microdosing expert Sena Maria of The Medicine of Being Human and MicrodosingForResilience.com. 

In this interview, we learn about Sena’s microdosing business, which helps people begin microdosing psilocybin (note she does not provide any illegal substances, only coaches people on how to microdose) and the benefits that microdosing can bring.

For example, Sena gives us a fantastic Top 5 Benefits of Microdosing at some point in our chat.

Some of the questions that we covered were: 
-What is microdosing and what are the benefits?
-How/ why did you start microdosing ?
-What is your microdosing regiment? 
-What benefits have you personally seen from this?
-What do you wish people knew about psychedelics that they don’t currently?
-Can Microdosing magic mushrooms help with addiction?
-Can microdosing help treat depression or anxiety?
 
On top of discussing the how and why of microdosing psychedelics, Sena also discussed how these medicines have been known for generations in some aboriginal tribes, and how Western Medicine may still have a lot to learn.

Timestamps
00:00- Intro
1:32 – Sena Maria’s journey to microdosing: From Google to Psychedelics
4:15- Microdosing For Resilience
5:58- How to microdose psilocybin
8:20- Top 5 benefits of Microdosing
13:31- What is missed in the psychedelics conversation?
18:34- Sena’s Psychedelic Ceremony experiences
22:05 – How did you integrate what you learned in your psychedelic ceremony

#Microdosing #MicrodosingBenefits #Psychedelics

Today’s episode for you focuses on why C-O FOUNDER and CEO JR Rahn founded Mindmed and on Reconstructing how we treat mental health in America.

MindMed, (MMED) on the Canadian NEO Stock exchange and (MMEDF) on the American Over the counter market has been experiencing a pull back lately. Remember what I said before: MindMed should be looked as a long term investment and is not for investors with weak stomachs!

During his recent appearance on Context 360 with Kevin O’Leary, MindMed’s Co-Ceo Jr Rahn made a sober prediction that the mental health crisis will only get worse.
-automation, sped up by the Rona virus, will depend our crisis of identity, and cause millions more to suffer. If we do nothing now, soon we could be living in a very dark world
-to reiterate a couple alarming stats; 40% have has a mental health incident or have addiction and 11% have considered committing suicide. This is terrifying, and only going to get worse. MindMed was founded with the vision to find a solution or rather multiple solutions to these mental problems. If successful, the company stands to take the biotech industry by storm and we, as psychedelic investors, will reap the returns.

https://www.youtube.com/watch?v=mNfq6eEUT7Q&t=459s&ab_channel=ContextLive

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF

Who’s winning the psychedelics race and how do clinical trials work? This topic has been requested a lot lately so we decided to give you a rundown on the clinical trials system and the psychedelic-inspired companies who are furthest advanced at the moment. Of course, for now, MAPS is leading the race. However, other public companies such as Compass Pathways (CMPS) and MindMed (MMED / MNMD) are not far behind, for now.

Hopefully, this introductory video will help some new retail investors who are considering investing in biotech companies who do not te have an approved drug, to understand the importance that clinical trials need to play in their investing decisions.

Timestamps:
0:00 – Intro
1:34 – What is the clinical trial system?
2:15 – Preclinical
3:00 – Phase 0
3:32 – Phase I
5:45 – Phase II
8:26 – Phase III
10:28 – Phase IV
11:08 – Who’s winning the race?
11:16 – MAPS ( non-for-profit entity): Has already completed a Phase III study on MDMA to treat PTSD
12:02 – Compass Pathways (CMPS) has a Phase IIb trial to treat TRD with COMP360
12:28 – MindMed (MMED / MNMD) has completed a Phase IIa LSD study to treat Anxiety and will begin phase IIb this year. MindMed also has other Phase II studies involving LSD & Ibogaine (18-MC)
13:23 – Mydecine (MYCO) and CYBIN (CYBN) following suit

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #Numi #CMPS

In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast.

In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health?

The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression?

Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect.

Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects.

It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year.

James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity.

In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now.

Enjoy the episode!

Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Cybin #Psilocybin #Psychedelics